Elanco Animal Health Inc (ELAN) — SEC Filings

Latest SEC filings for Elanco Animal Health Inc (ELAN), explained in plain English.

Sentiment Overview: 1 bullish, 32 neutral, 2 mixed

Recent Filings (35)

• Elanco Director Exercises Stock Options — 4 · 2026-04-02T16:02:28-04:00 [neutral] Risk: low
  On March 31, 2026, Anand Kapila, a director at Elanco Animal Health Inc., reported a change in beneficial ownership of securities. The filing details the acquis
• Elanco Insider VanHimbergen Files Form 4 on March 20, 2026 — 4 · 2026-03-24T16:31:49-04:00 [neutral]
  This Form 4 filing, dated March 24, 2026, indicates a change in beneficial ownership for Robert M. VanHimbergen, an insider at Elanco Animal Health Inc. (ELAN).
• Elanco Animal Health Files 8-K on Exit Costs — 8-K · 2025-12-09T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated filed an 8-K on December 9, 2025, reporting on cost associated with exit or disposal activities and Regulation FD disclosures
• Elanco Swings to Q3 Loss Amidst Divestiture Absence, Revenue Up 10% — 10-Q · 2025-11-05T00:00:00.000Z [mixed] Risk: medium
  Elanco Animal Health Inc. reported a net loss of $34 million for the three months ended September 30, 2025, a significant decline from the net income of $364 mi
• Elanco Animal Health Files 8-K: Material Agreement & Financial Obligations — 8-K · 2025-11-03T00:00:00.000Z [neutral] Risk: medium
  On October 31, 2025, Elanco Animal Health Incorporated entered into a material definitive agreement. This filing also indicates the creation of a direct financi
• Elanco Narrows Q2 Loss to $10M Amidst Mixed Segment Performance — 10-Q · 2025-08-07T00:00:00.000Z [mixed] Risk: medium
  Elanco Animal Health Inc. reported a net loss of $10.0 million for the second quarter of 2025, a significant improvement from the net loss of $50.0 million in t
• Elanco Animal Health Enters Material Agreement — 8-K · 2025-06-26T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated entered into a material definitive agreement on June 25, 2025. This filing also indicates the creation of a direct financial o
• Elanco Animal Health CFO Departs; Interim Appointed — 8-K · 2025-05-28T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated announced on May 21, 2025, the departure of its Chief Financial Officer, Todd M. Young. The company has appointed Oliver G. Go
• Elanco Animal Health Files 8-K on Shareholder Votes — 8-K · 2025-05-21T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Incorporated filed an 8-K on May 21, 2025, reporting on matters submitted to a vote of security holders as of May 16, 2025. The filing deta
• Elanco Animal Health Files Q1 2025 10-Q — 10-Q · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. filed its 10-Q for the period ending March 31, 2025. The filing covers the first quarter of 2025, detailing financial performance and
• Elanco Animal Health Executive Compensation Details — DEF 14A · 2025-03-27T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. filed its DEF 14A on March 27, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
• Elanco Animal Health Inc. Announces Executive and Board Changes — 8-K · 2025-03-17T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated announced on March 11, 2025, a significant event involving the departure of directors or certain officers, the election of new
• Elanco Animal Health Files 2024 10-K — 10-K · 2025-02-25T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Greenfi
• Elanco Animal Health Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Incorporated filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing detai
• Elanco Animal Health Announces Board and Executive Changes — 8-K · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated announced on November 11, 2024, changes in its board of directors and executive compensation arrangements. The filing details
• Elanco Animal Health Q3 2024 10-Q Filing — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. reported its financial results for the period ending September 30, 2024. The company's filing covers the third quarter of 2024, detail
• Elanco Animal Health Files 8-K — 8-K · 2024-10-16T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Incorporated filed an 8-K on October 16, 2024, to report information under Regulation FD. The filing does not contain specific financial fi
• Elanco Animal Health Enters Material Definitive Agreement — 8-K · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. entered into a material definitive agreement on August 13, 2024, related to a financial obligation. The company, headquartered in Gree
• Elanco Animal Health Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter of 2024, detailing financial performance and
• Elanco Completes Bayer Animal Health Acquisition — 8-K · 2024-07-09T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated announced the completion of its acquisition of Bayer Animal Health on July 9, 2024. This strategic move is expected to signifi
• SC 13G/A Filing — SC 13G/A · 2024-07-08T00:00:00.000Z [neutral]
• Elanco Animal Health Enters Material Definitive Agreement — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. entered into a material definitive agreement on July 3, 2024, related to a direct financial obligation. The company, headquartered in
• Elanco Animal Health Announces Corporate Changes and Filings — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Incorporated announced on May 30, 2024, a series of significant corporate actions. These include the election of new directors, the appoint
• Elanco Animal Health Q1 2024 10-Q Filing — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's financial performance for the quarter is detailed in thi
• Elanco Animal Health Files 2024 Proxy Statement — DEF 14A · 2024-04-19T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. filed its definitive proxy statement (DEF 14A) on April 19, 2024, for its annual meeting on May 30, 2024. The filing details the compa
• Elanco Appoints New Chief Legal Officer — 8-K · 2024-04-01T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. announced on March 29, 2024, the appointment of Ms. Katharine P. (Kate) Nealon as Executive Vice President, Chief Legal Officer and Co
• Elanco Files Definitive Additional Proxy Materials — DEFA14A · 2024-02-29T00:00:00.000Z [neutral] Risk: low
  Elanco Animal Health Inc. filed a DEFA14A on February 29, 2024, indicating definitive additional materials for a proxy statement. The filing includes a press re
• Elanco Animal Health Files 8-K on Operations and Exit Costs — 8-K · 2024-02-26T00:00:00.000Z [neutral] Risk: medium
  Elanco Animal Health Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition, as well as costs associated with ex
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• PRIMECAP Boosts Elanco Stake to 10.3%, Holding 50.6M Shares — SC 13G/A · 2024-02-12T00:00:00.000Z [bullish] Risk: low
  PRIMECAP Management Company, an investment firm based in Pasadena, CA, filed an amended SC 13G/A on February 12, 2024, disclosing its ownership in Elanco Animal
• Elanco Files 8-K on Material Agreement & Reg FD Disclosure — 8-K · 2024-02-05T00:00:00.000Z [neutral]
  Elanco Animal Health Inc. filed an 8-K on February 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the
• BlackRock Discloses Significant Stake in Elanco Animal Health — SC 13G · 2024-01-29T00:00:00.000Z [neutral]
  BlackRock Inc. filed an SC 13G on January 29, 2024, disclosing its ownership of Elanco Animal Health Inc. common stock as of December 31, 2023. This filing indi
• Elanco Confirms NYSE Listing for Common Stock & Equity Units — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Elanco Animal Health Inc. filed an 8-K on January 8, 2024, to disclose that its Common Stock and 5.00% Tangible Equity Units are both registered on the New York
• Elanco Files Routine 8-K; Confirms Non-Emerging Growth Status — 8-K · 2024-01-02T00:00:00.000Z [neutral]
  Elanco Animal Health Incorporated filed an 8-K on January 2, 2024, primarily to disclose general corporate information and confirm its status as a non-emerging